particle standard Search Results


spheres ps227  (LGC Standards)
90
LGC Standards spheres ps227
Spheres Ps227, supplied by LGC Standards, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/10__1002_slash_ceat__201900311-82-98-59?v=LGC+Standards
Average 90 stars, based on 1 article reviews
spheres ps227 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
sodium chloride  (Chem Impex International)
95
Chem Impex International sodium chloride
Sodium Chloride, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/10__3390_slash_molecules30112371-160-26-29?v=Chem+Impex+International
Average 95 stars, based on 1 article reviews
sodium chloride - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
paclitaxel  (Chem Impex International)
95
Chem Impex International paclitaxel
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Paclitaxel, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pmc07596148-84-17-21?v=Chem+Impex+International
Average 95 stars, based on 1 article reviews
paclitaxel - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
standard size particles 4210a  (Moritex Corporation)
90
Moritex Corporation standard size particles 4210a
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Standard Size Particles 4210a, supplied by Moritex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/us07182552-139-24-30?v=Moritex+Corporation
Average 90 stars, based on 1 article reviews
standard size particles 4210a - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
standard size particles 4250a  (Moritex Corporation)
90
Moritex Corporation standard size particles 4250a
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Standard Size Particles 4250a, supplied by Moritex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/us07182552-151-24-30?v=Moritex+Corporation
Average 90 stars, based on 1 article reviews
standard size particles 4250a - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
kcl particle removal efficiency by particle size  (ASHRAE Inc)
90
ASHRAE Inc kcl particle removal efficiency by particle size
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Kcl Particle Removal Efficiency By Particle Size, supplied by ASHRAE Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/us10543447-87-142-145?v=ASHRAE+Inc
Average 90 stars, based on 1 article reviews
kcl particle removal efficiency by particle size - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
standard calibration nanoparticle solution  (Particle Metrix)
90
Particle Metrix standard calibration nanoparticle solution
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Standard Calibration Nanoparticle Solution, supplied by Particle Metrix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pmc10244507-63-15-21?v=Particle+Metrix
Average 90 stars, based on 1 article reviews
standard calibration nanoparticle solution - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
nanostandards standard particles 700074  (Particle Metrix)
90
Particle Metrix nanostandards standard particles 700074
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Nanostandards Standard Particles 700074, supplied by Particle Metrix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pmc10867254-32-1-5?v=Particle+Metrix
Average 90 stars, based on 1 article reviews
nanostandards standard particles 700074 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
polystyrene latex particles  (JSR Corporation)
90
JSR Corporation polystyrene latex particles
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Polystyrene Latex Particles, supplied by JSR Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pm15514091-42-3-16?v=JSR+Corporation
Average 90 stars, based on 1 article reviews
polystyrene latex particles - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
polystyrene particle size standards  (Applied Microspheres BV)
90
Applied Microspheres BV polystyrene particle size standards
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Polystyrene Particle Size Standards, supplied by Applied Microspheres BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pm39892598-102-10-14?v=Applied+Microspheres+BV
Average 90 stars, based on 1 article reviews
polystyrene particle size standards - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
100-nm polystyrene latex microbeads  (Particle Metrix)
90
Particle Metrix 100-nm polystyrene latex microbeads
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
100 Nm Polystyrene Latex Microbeads, supplied by Particle Metrix, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pmc11080878-182-22-25?v=Particle+Metrix
Average 90 stars, based on 1 article reviews
100-nm polystyrene latex microbeads - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
silica standard particles 0.2 :m (200)  (MicroMod Partikeltechnologie GmbH)
90
MicroMod Partikeltechnologie GmbH silica standard particles 0.2 :m (200)
Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), <t>Paclitaxel</t> (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.
Silica Standard Particles 0.2 :M (200), supplied by MicroMod Partikeltechnologie GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/particle+standard/pm25449441-25-7-20?v=MicroMod+Partikeltechnologie+GmbH
Average 90 stars, based on 1 article reviews
silica standard particles 0.2 :m (200) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Journal: Cellular and Molecular Bioengineering

Article Title: Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

doi: 10.1007/s12195-020-00626-z

Figure Lengend Snippet: Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Article Snippet: 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), Fmoc-protected amino acids, N,N 0 -diisopropylcarbodiimide (DIC), O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU), N,N -dimethylformamide (DMF), and Paclitaxel were purchased from Chem-Impex International, Inc. RPMI-1640, M199, trypsin and EDTA solution, Antibiotic-Antimycotic Solution, ultra-low attachment (ULA) plates, and 1× phosphate buffered saline (PBS) were purchased from Corning.

Techniques: Concentration Assay, Comparison, Activity Assay, Derivative Assay, Cell Culture